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Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal admin­
istration (five times at 15 mg kg of body weight“ 1 every other day) of the in vitro active antimalarial acyclic 
nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]. Toxicological 
studies showed that the main cause of death resulted from (S)-HPMPA-induced nephrotoxicity. Although 
concomitant intraperitoneal administration of the tubular epithelium transport blocker probenecid prevented 
(S)-HPMPA-induced toxicity, mice eventually died with a high level of parasitemia, despite repeated admin­
istration of high doses of (S)-HPMPA. The short half-life of (S)-HPMPA in plasma combined with the 
insusceptibility of the nonreplicative stages of the parasite to (S)-HPMPA could explain this failure to 
eradicate all parasites. Indeed, a low but sustained (calculated) level of 200 nM (S)-HPMPA in plasma 
completely cured P. berghei-infected mice. However, these mice, which received a total dose of only 28 mg kg-1 
administered via osmotic pumps for 7 days, died because of the toxicity of the drug. These findings indicate that 
nephrotoxicity hinders the use of (S)-HPMPA as a drug against blood stage parasites. An alternative appli­
cation of (S)-HPMPA as a potent prophylactic drug is discussed.
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Infection with species of the protozoan parasite Plasmodium repeatedly (15). (S)-9-(3-hydroxy-2-phosphonylmethoxypro-
threatens approximately one-fourth of the world’s population. pyl)cytosine [(S)-HPMPC]-induced nephrotoxicity has been
A rapidly developing resistance of the parasite to formerly 
effective drugs stresses the need for the development of new 
antimalarial compounds. Previous work showed that the
nucleoside phosphonate (£)-9-(3-hydroxy-2-phos-
adenine [(S')-HPMPA], the prodrug 
the diphosphorylated active compound, is a potent inhib- 
of mid-schizont stages of both P. falciparum and P.
Repeated intraperitoneal administration (four
of 20 mg of (S)-HPMPA kg of body weight
initial
attributed to the active uptake of acyclic nucleotide analogs by 
organic anion transporters present at both the basolateral and 
the brush border membranes of the proximal convoluted tu­
bule cell (6). Cyclic derivation of (S)-HPMPC, resulting in a 
modification of its charge, elevated the therapeutic index (6). 
Inhibition of (S)-HPMPC uptake by the organic anion trans­
port blocker probenecid also reduced nephrotoxicity (6, 12, 
14). Depending on the ratio between tubular secretion and 
reabsorption of a drug in the presence of probenecid, concom­
itant administration of probenecid can result in an elevation of 
the level of the drug in plasma and the half-lives of several 
drugs in plasma (10), including nucleoside and nucleotide an­
alogs like zidovudine (17) and (5>HPMPC (8). Therefore, in
the case of P. berghei cotreatment with probenecid not only 
could reduce or prevent (S)-HPMPA-induced nephrotoxicity 
but also could increase the effectiveness of (5)-HPMPA on 
after treatment was stopped. Two conditions in asynchronous infections. This report describes the toxicologi
^  1 /  * #■ (esti-
in plasma, 0.1 mM, or «=»1,200 times the
concentration [IC5()] for in vitro-cultured P.
strongly suppressed parasitemia in P. 
BALB/c mice but did not eliminate all par-
this treatment resulted in almost
ation of parasites, some of the mice which 
infected with small numbers of parasites (<0.1 %)
surviving mice developed increasing levels of
cal effects and antimalarial efficacies of different regimens of 
t half-life in plasma (5 to 10 min) of acyclic nucle- (,S)-HPMPA in the presence and absence of probenecid.
concert may account for the failure of radical treatment: (i) 
the
oside phosphonates (4, 15, 16) and (ii) a narrow window of
susceptibility of erythrocytic parasites to (S)-HPMPA, with 
schizonts, which constitute a minor part of an asynchronous
pari population, inhibited only by (£)-HPMPA MATERIALS AND METHODS
Death after repeated (S)-HPMPA administration, despite 
minimal parasitemia, suggests toxicity. The nephrotoxicity of 
acyclic nucleoside phosphonates has been described in mice
and humans (12-14), especially when it is administered
Si! Corresponding author. Mailing address: P.O. Box 80165, 3508 TD
Utrecht, The Phone: 30-2532559. Fax: 30-2540784.
(S)-HPMPA and (S)-cHPMPA. (S)-HPMPA and (S)-cyclic-HPMPA [(5)- 
cHPMPA] were synthesized by A. Holy (Academy of Science, Prague, Czech 
Republic) and were obtained directly from him or from E. de Clercq (Rega 
Institute, Leuven, Belgium). For the structure of cyclic derivation, see the report 
by Bischofberger et al, (6).
Toxicological studies. BALB/c mice were exposed to different doses of intra- 
peritoneally (i.p.) administered (S)-HPMPA on the days indicated in the legend 
to Fig, 1. Mice were observed daily for clinical signs, and their body weights were 
determined on the indicated days. Two mice exposed to four times 80 mg of
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FIG. 1. Effect o f (iV)-HFMPA on body weights of BALB/e mice (10 mice per
group) after i.p. administration of 10 (A), 20 ( • ) ,  40 (■) and 80 (▼) mg of  
(A’)-HPMPA kg 1 on clays 0, 4, 7, and 11. The range of the standard deviation 
(not shown) was 0.9 to 2.5 g. The body weights of nontreated mice were deter­
mined up to day 21. Their average body weight (25.9 g) did not increase between 
day 14 and day 21.
HPMPA kg“ 1 (Fig. 1) as well as two control mice were bled on day 21 after the 
start of treatment for analysis of enzyme and biochemical parameters (Table 1), 
and immediately afterward, these mice were sacrificed for general pathological 
and histopathological examination.
Infection and determination of parasitemia. Mice were infected by i.p. injec­
tion of P. herghei ANK A blood stages. Parasitemia was determined by micro­
scopic examination of Giemsa-stained blood smears.
i.p. drug treatment. BALB/c mice (six mice per group) infected with 
parasites on day 0 were treated every other day, starting on day 2, by i.p. injection
)« * (0.285 gof (S)-HPMPA, (S)-cHPMPA (both at 15 mg kg 1
'). Separate groups of mice received probenecid (0.285 g kg ') 30 min prior
to (iS)-HPMPA or (.V)-cHPMPA administration. A control group of six infected 
mice was not exposed to any treatment (previous experiments had shown that i.p.
it ion of phosphate-buffered saline [PBS] had no effect on the course of  
. Mice were observed for clinical signs and were weighed every day. 
Sustained administration of (iS)-HPMPA. Osmotic pumps (effective volume, 
170 jxl; release, 1 jjil h 1 for 7 days; model 2001; Alza Corporation, Palo Alto, 
Calif.) containing 7.5 or 15 rnM (kS’)-I IPMPA were implanted i.p
to
10* parasites. Nontreated control mice
mice on d a v ..1. Mice were infected on day 0
not receive
previous experiments had shown that implanted pumps containing 
affect the course of infection. Mice were observed for clinical
ause
do not
daily. The release (R
asma
pump ) of (vV)-HPMPA
i.«e
:tng the levels in
X t in? «M
ated in Table 2 was calculated by the following equation; R
u r n  * l i < i i 11" * ) (  ' { t n  ! Ì 11*t* * \ V  1 /  /  i n  I i t i »  r e  1.- u  ' \Cm (in moles liter 1 ) x V (in liters
p u mp ( i n
) x ■*)
), where C'NH is the steady-state concentration in plasma, V is the 
volume of distribution, and r, , is the half-life. The half-life of (.S*) -1 IPMPA in
-I >• * *
plasma (10 min) was determined in rats (4). The volume of distribution (K) was 
assumed to be 0.7 liters kg A release of 1 fxl o f 15 inM (S)-lIPMPA h 1
*e res
I i t e r i
in a steady-state concentration in plasma of 0.2 ti. .1M.,'■? Vi 10 (i
* which equals ± 2.5 times the K'«U) for l\ herghei in vitro.
In the ; experiment, BALB/c mice were infected with 10*’ parasites on
day 0, and sustained (5)-HPMPA treatment [effective volume, 87 |xl; release, I 
jjlI h 1 of 15 or 30 mM (S)-HPMPA for 3.5 days; model 1003D; Alza Corpora­
tion] was started on day 2.
RESULTS
Toxicology studies. To of death of P.
low
effects of the drug were
i.p. (S)-HPMPA
ited loss of body 
ifter the
mice which occurred during (5)-I
parasitemia,
in
an
toxicological
W.l|r
mice. Repeated
and
a ma tic
in weight occurred
substantial
a 3-month lag period. A
in weight was observed £ r i n i t i a 1
I arapid increase in the group treated with 40 mg 
lyze the cause of the (S)-HPMPA-induced toxicity further, two
iiiced for
il eve
80 mg kg 
H is t opa t h o 1 ogi c a 1 ex 
degeneration tubule
The tubular lumina were are
proteinaceous material. No 
glomeruli. Both mice showed cataract of the 
showed parenchymal necrosis as
in
karyomegatosis, indicating 
Hepatotoxicity was confirmed by the
restoration 'generation 
levels of liver
specific enzymes phosp hatases, a 1 a n in e
i n d
plasma lble, and aspartate aminotn 
The small and large 
showed no abnormalities.
Effect of concomitant (S)-HPMPA and probenecid adminis­
tration.
toxicity and antiplasmodial elficacy was analyzed
. The administration of 
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11^ 1. Levels of various components in plasma at day 10 after of repeated i.p. treatment of BALB/e mice
Group* U rea (mmol liter
Creatinine
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(g liter ')
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(g liter" ' )
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The mice (Ml i M2) were treated four
Ml, M2, Ml, and H2, mice selected from
with 80
«I creatinine level could
of (.V)* HPMPA 
depicted in Fig. I.
i . Experiment was conducted as
termined in the icteric blood samples of (.V)-HPMPA-treated mice.
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infection
Animal Calculated (S)-HPMPA  level in plasma (nM /'
% Pai•asitemia on the following day
postinfection: Day‘
4 5 6 7 8 9 19
M l 200 < 0 .1 0 0 0 0 0 13
M 2 200 < 0 .1 0 0 0 0 0 14
M3 200 0 0 0 0 0 0 16
M 4 100 < 0 .1 0.1 0.1 0.1 0.1 < 0 .1 10 28
M 5 100 0.1 0.2 0 .2 1 1 1 17 27
M 6 100 0.1 0.2 0.3 0.5 0.5 0 7 22
M 7 N o n e 0.3 1 4 9 9 9 50 25
M 8
M 9
N o n e 
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FIG. o*#♦
HPMPA plus probenecid on P. berghei parasitemia in BALB/c mice. The exper-
ti
/>
C
O as in Materials and Methods.
mice (A), mice treated with (S)-HPMPA (15 mg kg 1 ), (
I \ ,and mice 
( • ) .  The DISCUSSION
Repeated i.p. administration of the acyclic nucleoside phos
tions.
phonate (S)-HPMPA, which inhibits the growth of
(S)-cHPMPA plus probenecid and nontreated mice was 
(range, days 6 to 9). The mean days of death in mice treated with (<S)-HPMPA 
and (5)-HPMPA plus probenecid were 
to 26) postinfection, respectively. All differences were highly significant (for all, 
P =
cultured Plasmodium parasites, induces a dose-related loss of 
body weight in noninfected mice. The acute loss of weight 
observed in all treated groups and the fast (10 and 20 mg 
kg-1), biphasic (40 mg kg” 1), and slow (80 mg kg“ 1) recovery 
of body weight afterward indicate that (»S^-HPMPA induces 
acute as well as long-term adverse physiological effects. His-
treatment with probenecid, 24.7 ± 1.7 and 19.2 ± 
spectively).
re- mg kg every third or fourth day demonstrated that (5)- 
HPMPA induced hepatotoxicity and severe nephrotoxicity. 
In the presence of probenecid treatment, the level of para- The degeneration of tubular epithelial cells in the kidneys must
sitemia again started to increase from day 9 postinfection, be the of weight (iS)-HPMPA-in-
concomitant treatment, in mice duced hepatotoxicity was less severe and the regeneration of 
liver cells could
creased until the mice died. Because the concomitant admin­
istration of ’ .runs in sorption of glucose, amino acids, i
airs not only the reab-
but also that of
water
(S)-HPMPA treatment alone might 
indirect mechanism different
; an acute loss of weight, as was observed in the
observed in
in mice
in
no
mice.
10 mice treated four
ast, mortality did occur
(S)-HPMPA must
because the
an with a
administration in vitro IC50
idministered
driven pumps, in
mice. The in Table
from P.
estimated
(±1.25 times the IC50 for in vitro-cultured P. herghei parasites)
, However,
only a twofold increase in the constant level in plasma caused 
radical cure. Despite this effectiveness, mice did not survive but 
died 15 days, on average, after the start of treatment (Table 2). 
An additional experiment showed that a twofold reduction in
amount 
despite 
posed for 7 to sustained (5)-HPMPA (in
vals compared with the <
mter- 
same amount as
not eradicating
not shown).
suggested an 
were crenated.
The cause of the sudden rise in the level of parasitemia seen 
from day 9 postinfection onward in mice 
neously with (S)-HPMPA and probenecid (Fig. 2) remains to 
be elucidated. An infection-induced increase in the relative 
amount of reticulocytes, for which P. 
preference (11)
may play a role,
of (S)-HPMPA
group, which in the organic
anion-
ney, were activities. Repeated
however
HPMPA, allowing the use of even much lower doses. Such an
analogs like (S)-HPMPA as effective prophylactic drugs, even 
if they are administered on an infrequent basis since, in con­
trast to their short half-lives in plasma, the intracellular half-
3).
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